Adverse Events & Serological Responses Following SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease

Ante Markovinović; Joshua Quan; Michelle Herauf; Lindsay Hracs; Joseph W Windsor; Nastaran Sharifi; Stephanie Coward; Léa Caplan; Julia Gorospe; Kenneth Ernest-Suarez; Christopher Ma; Remo Panaccione; Richard J M Ingram; Jamil N Kanji; Graham Tipples; Jessalyn K Holodinsky; Charles N Bernstein; Douglas J Mahoney; Sasha Bernatsky; Eric I Benchimol; Gilaad G Kaplan; STOP COVID-19 in IBD Research Group; STOP COVID-19 in IBD Research Group

doi:10.14309/ajg.0000000000002337

Adverse Events & Serological Responses Following SARS-CoV-2 Vaccination in Individuals with Inflammatory Bowel Disease

Am J Gastroenterol. 2023 May 22. doi: 10.14309/ajg.0000000000002337. Online ahead of print.

Authors

Ante Markovinović¹, Joshua Quan¹, Michelle Herauf¹, Lindsay Hracs¹, Joseph W Windsor¹, Nastaran Sharifi¹, Stephanie Coward¹, Léa Caplan¹, Julia Gorospe¹, Kenneth Ernest-Suarez¹, Christopher Ma¹, Remo Panaccione¹, Richard J M Ingram¹, Jamil N Kanji^{2

3

4}, Graham Tipples^{2

5}, Jessalyn K Holodinsky⁶, Charles N Bernstein⁷, Douglas J Mahoney⁸, Sasha Bernatsky⁹, Eric I Benchimol^{1

2

3

4

5

6

7

8

9

10

11

12}, Gilaad G Kaplan¹; STOP COVID-19 in IBD Research Group; STOP COVID-19 in IBD Research Group

Affiliations

¹ Inflammatory Bowel Disease Clinic, Department of Medicine, University of Calgary, Calgary, Alberta.
² Alberta Precision Laboratories, Public Health Laboratory, Alberta, Canada.
³ Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
⁴ Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁵ Department of Medical Microbiology and Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
⁶ Department of Clinical Neuroscience, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta.
⁷ University of Manitoba IBD Clinical and Research Centre and Department of Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
⁸ Department of Microbiology, Immunology and Infectious Disease, University of Calgary, Calgary, Alberta.
⁹ Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
¹⁰ ICES, Toronto, ON, Canada.
¹¹ SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON, Canada.
¹² Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.

PMID: 37216598
DOI: 10.14309/ajg.0000000000002337

Abstract

Objectives: We determine adverse events following 4 doses of SARS-CoV-2 vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare.

Methods: Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titres and ISR.

Results: Severe adverse events occurred in 0.03%. ISR was significantly associated with antibody levels following 4th dose (GMR= 2.56; 95% CI: 1.18, 5.57). No cases of IBD flare occurred.

Conclusions: SARS-CoV-2 vaccines are safe for those with IBD. ISRs following 4th dose may indicate increased antibodies.